# Praxis Precision Medicines Inc. (PRAX)

Source: https://www.quantisnow.com/company/PRAX
Generated: 2026-11-16T00:40:06.981Z

- Ticker: PRAX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001689548
- Website: praxismedicines.com

## About

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

## Latest PRAX news and filings

- 2026-11-12 22:01 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-regulation-fd-6788724)
- 2026-11-12 21:30 UTC [Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day](https://www.quantisnow.com/insight/praxis-precision-medicines-details-launch-readiness-for-relutrigine-and-ulixacaltamide-6788348)
- 2026-11-12 12:13 UTC [Promo] [A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End](https://www.quantisnow.com/insight/a-run-of-fda-target-dates-fills-the-biotech-calendar-6786152)
- 2026-11-09 21:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Praxis Precision Medicines Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-praxis-precision-medicines-inc-6781756)
- 2026-11-09 12:02 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-results-of-6780137)
- 2026-11-09 12:00 UTC [Earnings] [Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-6780093)
- 2026-11-05 18:24 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-praxis-precision-medicines-6775618)
- 2026-11-04 21:01 UTC [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-6772143)
- 2026-10-27 20:01 UTC [Conference Announcement] [Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation](https://www.quantisnow.com/insight/praxis-precision-medicines-announces-third-quarter-2026-financial-results-date-6759085)
- 2026-10-16 12:46 UTC [Analyst Coverage Initiated] [Analyst initiated coverage on Praxis Precision Medicines with a new price target](https://www.quantisnow.com/insight/analyst-initiated-coverage-on-praxis-precision-medicines-with-a-new-6748796)
- 2026-10-15 13:26 UTC [Analyst Coverage Initiated] [UBS initiated coverage on Praxis Precision Medicines with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-praxis-precision-medicines-with-a-new-6747621)
- 2026-10-02 20:01 UTC [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-6734211)
- 2026-09-03 20:01 UTC [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-6704979)
- 2026-08-14 18:08 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-praxis-precision-medicines-6682687)
- 2026-08-06 12:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Praxis Precision Medicines Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-praxis-precision-medicines-inc-6667684)
- 2026-08-06 12:31 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-results-of-6667676)
- 2026-08-06 12:00 UTC [Public Offering] [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-6667388)
- 2026-08-04 20:01 UTC [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-6661843)
- 2026-07-30 20:01 UTC [Earnings Date] [Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://www.quantisnow.com/insight/praxis-precision-medicines-to-report-second-quarter-2026-financial-results-6655881)
- 2026-07-13 13:09 UTC [Analyst Coverage Initiated] [Goldman initiated coverage on Praxis Precision Medicines with a new price target](https://www.quantisnow.com/insight/goldman-initiated-coverage-on-praxis-precision-medicines-with-a-new-6635038)
- 2026-07-08 20:56 UTC [SEC Form 4] [Chief Executive Officer Souza Marcio gifted 23,121 shares, decreasing direct ownership by 27% to 56,495 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-souza-marcio-gifted-23121-shares-decreasing-direct-6631788)
- 2026-07-07 21:05 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-other-events-6630392)
- 2026-07-07 12:00 UTC [Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor](https://www.quantisnow.com/insight/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-6629450)
- 2026-07-02 20:30 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-changes-in-6625766)
- 2026-07-02 20:01 UTC [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-6624966)
- 2026-06-29 20:40 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-other-events-6619231)
- 2026-06-29 20:30 UTC [Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies](https://www.quantisnow.com/insight/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-6619113)
- 2026-06-26 21:09 UTC [SEC Form 4] [Director Desimone Jill exercised 11,600 shares at a strike of $71.20 and sold $3,611,335 worth of shares (11,600 units at $311.32) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-desimone-jill-exercised-11600-shares-at-a-strike-of-6617729)
- 2026-06-22 20:43 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-other-events-6611000)
- 2026-06-22 12:00 UTC [Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants](https://www.quantisnow.com/insight/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-elsunersen-6610050)
- 2026-06-18 12:19 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Praxis Precision Medicines with a new price target](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-praxis-precision-medicines-with-6608015)
- 2026-06-12 21:24 UTC [SEC Form 4] [Director Arbuckle Stuart A was granted 1,371 shares, increasing direct ownership by 118% to 2,537 units (SEC Form 4)](https://www.quantisnow.com/insight/director-arbuckle-stuart-a-was-granted-1371-shares-increasing-direct-6601173)
- 2026-06-12 21:24 UTC [SEC Form 4] [Director Chodakewitz Jeffrey was granted 1,371 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-chodakewitz-jeffrey-was-granted-1371-shares-sec-form-4-6601172)
- 2026-06-12 21:24 UTC [SEC Form 4] [Director Young William D was granted 1,371 shares, increasing direct ownership by 72% to 3,269 units (SEC Form 4)](https://www.quantisnow.com/insight/director-young-william-d-was-granted-1371-shares-increasing-direct-6601170)
- 2026-06-12 21:24 UTC [SEC Form 4] [Director Cudkowicz Merit Ester was granted 1,371 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-cudkowicz-merit-ester-was-granted-1371-shares-sec-form-6601167)
- 2026-06-12 21:24 UTC [SEC Form 4] [Director Desimone Jill was granted 1,371 shares, increasing direct ownership by 142% to 2,337 units (SEC Form 4)](https://www.quantisnow.com/insight/director-desimone-jill-was-granted-1371-shares-increasing-direct-ownership-6601166)
- 2026-06-12 21:23 UTC [SEC Form 4] [Director Kindler Jeffrey B was granted 1,371 shares, increasing direct ownership by 118% to 2,537 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kindler-jeffrey-b-was-granted-1371-shares-increasing-direct-6601165)
- 2026-06-12 21:23 UTC [SEC Form 4] [Director Mitchell Dean J was granted 1,371 shares, increasing direct ownership by 8% to 18,622 units (SEC Form 4)](https://www.quantisnow.com/insight/director-mitchell-dean-j-was-granted-1371-shares-increasing-direct-6601164)
- 2026-06-12 21:23 UTC [SEC Form 4] [Director Norden Gregory was granted 1,371 shares, increasing direct ownership by 729% to 1,559 units (SEC Form 4)](https://www.quantisnow.com/insight/director-norden-gregory-was-granted-1371-shares-increasing-direct-ownership-6601161)
- 2026-06-12 20:46 UTC [SEC Form 8-K] [Praxis Precision Medicines Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/praxis-precision-medicines-inc-filed-sec-form-8-k-submission-of-6600840)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PRAX
- Earnings history: https://www.quantisnow.com/earnings/PRAX
- Dividend history: https://www.quantisnow.com/dividends/PRAX
- Insider transactions: https://www.quantisnow.com/insiders/PRAX
- Options chain: https://www.quantisnow.com/options/PRAX
- SEC 8-K filings only: https://www.quantisnow.com/company/PRAX/8-k
- RSS and alerts for PRAX: https://www.quantisnow.com/docs/rss-feeds.md
